About Us
Myelofibrosis
- Overview
- Burden of Anemia
Momelotinib
Patients
- MOMENTUM Clinical Trial
- Expanded Access Protocol
Investors
Careers

company
Science
- Science Overview
- DDR
Development
Investors

Building MOMENTUM for Patients with Myelofibrosis

Learn More

CORPORATE PRESENTATION

Learn more about Sierra Oncology and momelotinib

View Presentation

Recent News

02

Oct

Sierra Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14

Sep

Sierra to Present at September Investor Conferences

06

Aug

Sierra Oncology Strengthens Management Team to Implement North American Pre-Commercialization Strategy for Momelotinib

06

Aug

Sierra Oncology Reports Second Quarter 2020 Results

28

Jul

Sierra Oncology Appoints Christina Thomson as General Counsel

12

Jun

Sierra Oncology Reports Favorable Long-Term Safety and Dose Intensity Data for Momelotinib

Momelotinib

TARGETING JAK1/2 AND ACVR1

Learn More

Learn about Myelofibrosis

Learn More

Patient Resources

Learn More

About Us

Overview
Leadership
Board of Directors
Careers
Contact Us

Follow Us

Myelofibrosis

Overview
Burden of Anemia

Momelotinib

Overview
Mechanism
Publications

Patients

MOMENTUM Clinical Trial
Expanded Access Protocol

Investors

News Releases
Events & Webcast
Presentations
Publications
Financial Reporting
Stock Information
Corporate Governance
FAQs
Investor Alerts

Follow Us

Copyright © 2005-2019 Sierra Oncology, Inc. All Rights Reserved.

Privacy Notice
Terms of Use

Copyright © 2005-2019 Sierra Oncology, Inc. All Rights Reserved.